111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors.
Gianni Bussolati(University of Turin), Giovanni Paganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Angelo Nacca(University of Turin), Paola Cassoni(University of Turin), Bice Chini(Neuroscience Institute), Marco Chinol
PubMed
June 1, 2001
Cited by 13
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
|European Journal of Nuclear Medicine and Molecular Imaging|2014|465
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
|Journal of Neuroendocrinology|2012|424
A New Population of Parvocellular Oxytocin Neurons Controlling Magnocellular Neuron Activity and Inflammatory Pain Processing
|Neuron|2016|395
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390